December 1, 2021


Complete News World

Merck’s Accelerated Pill Review launched in Europe

According to clinical trials, this pill, called Molnupravir, can reduce the risk of coitus-19 associated with hospitalization and death.

The European Pharmaceutical Institute (EMA) on Monday announced the launch of a rapid review of the corona virus pill from the US laboratory Merck, making it an easy solution to become an important tool in the fight against infection.

“The EMA Committee on Medicinal Products for Human Use (CHMP) has begun an ongoing review of the oral antiviral drug Molnupravir. […] Developed by Merkel […] For the treatment of Govit-19 in adults ”, which makes it possible to expedite the process, the European Comptroller in Amsterdam said in a statement.

A big improvement

Preliminary results of laboratory and clinical studies “Prescribe medications to reduce the effectiveness of SARS-CoV-2 […] To prevent it from multiplying in the body, it can prevent Covid-19 patients from being hospitalized or dying, ”the European Pharmaceuticals Institute said.

If approved, this drug, called molnupravir, could make a significant improvement in reducing the more severe forms of the disease. Antivirals such as molluscum contagiosum reduce the ability of a virus to replicate, thereby reducing disease.

The treatment, which is given to patients within a few days of a positive test, halves the risk of hospitalization and death, according to a medical test conducted by Merck, also known as MSD outside the United States.

Already a requirement in the United States

EMA will evaluate Molnupravir’s compliance with standard European standards for performance, safety and quality.

October 11 Already, The U.S. pharmaceutical company announced that it had filed an emergency accreditation request with the U.S. Medical Agency, F.D.A. Anthony Fossie, a White House adviser on the health crisis, described the clinical trial data as “impressive.”

See also  Reinforcement of the Army with about fifty experts